Prof Mauro is a board-certified hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center. His clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. His patient care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with my patients and their referring providers to personalize decision-making and monitoring given the chronic nature of the disorders he treats. Dr Mauro's attendance is kindly supported by Novartis.

David Yeung is the head of haematology at the Royal Adelaide Hospital; Clinical Associate Professor at the Adelaide Medical School; and SA Cancer Council Beat Cancer Project Clinical Investigator at the South Australia Health and Medical Research Institute. David received his haematology and BMT training in Sydney, before completing his PhD studies in Adelaide on the optimal the use of tyrosine kinase inhibitors (TKI) as targeted therapy for chronic myeloid leukaemia (CML). David’s clinical research portfolio as principal investigator include several frontline TKI studies conducted through the Australasian Leukaemia and Lymphoma Group. With Prof Tim Hughes, A/Prof David Yeung leads one of the first trials to evaluate efficacy and safety of asciminib in newly diagnosed chronic phase CML. He is also the medical lead in a national project looking at genomics of high risk acute lymphoblastic leukaemia.

Dr Cecily Forsyth graduated in medicine from University of Sydney and completed advanced training in haematology at Royal Prince Alfred Hospital before moving to the Central Coast of NSW where she has worked as a clinical haematologist for over 25 years. She cares for patients with a wide range of malignant and non-malignant haematological issues with a particular passion for myeloproliferative neoplasms. She has contributed to several publications and clinical trials in MPNs. She provides holistic care to her patients and has an interest in the use of integrative medicine to improve symptoms and quality of life for patients with MPNs. Her other medical passions include facilitating clinical trial participation for patients living in regional and rural centres and improving patients’ access to information and education.